Faron Pharmaceuticals Oy (LON:FARN) Sets New 1-Year High - Time to Buy?

Faron Pharmaceuticals Oy (LON:FARN - Get Free Report)'s share price reached a new 52-week high on Monday . The company traded as high as GBX 252 ($3.35) and last traded at GBX 250 ($3.32), with a volume of 45377 shares traded. The stock had previously closed at GBX 239 ($3.18).

Faron Pharmaceuticals Oy Stock Performance

The company has a quick ratio of 1.09, a current ratio of 1.45 and a debt-to-equity ratio of 922.55. The stock has a fifty day moving average price of GBX 191.56 and a 200-day moving average price of GBX 185.89. The firm has a market cap of £285.15 million, a price-to-earnings ratio of -5.68 and a beta of 0.36.

About Faron Pharmaceuticals Oy

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.